Infectious herpes simplex virus (HSV) particles consist of three complex components: a DNA-containing nucleocapsid, an amorphous tegument layer composed of viral proteins, and a lipid bilayer envelope containing specific viral proteins. The nucleocapsid is produced in the nucleus of the infected cell and must then assemble with the other two components and egress from the cell. The process by which these components come together and leave the cell is poorly understood, but is generally accepted that the nucleocapsid first acquires an envelope by budding into the space between the inner and outer nuclear membranes (14) .
Several requirements for efficient envelopment at the inner nuclear membrane have been defined. This process apparently requires prior completion of the DNA packaging process. In wild-type virus-infected cells, empty capsids are only rarely enveloped (35) , and a variety of viral mutants that synthesize capsids but fail to package DNA do not efficiently envelop the empty capsids produced (2, 9, 11, 28, 29, 39) . A deletion in the gene encoding the virus-encoded alkaline nuclease results in failure to efficiently envelop DNA-containing capsids, suggesting that the packaging reaction may be incomplete and that completion is required in order to generate a nucleocapsid that is competent for envelopment (42) . Several other viral gene products have been reported to contribute to the process of primary envelopment. A recombinant HSV carrying a deletion in the U L 11 gene produces reduced numbers of enveloped virus particles, and an unusually high number of partial envelopment events are observed at the inner nuclear membrane, suggesting that U L 11 is required for efficient completion of the envelopment process (4) . Glycoprotein K (gK) plays a critical role in trafficking of enveloped virus particles through the cytoplasm in HSV-infected cells (22, 24) and may also play a role in primary envelopment, since complete deletion of gK results in overaccumulation of intranuclear nucleocapsids at very late times after infection (24) . Brown et al. have reported that a deletion in the gene encoding ICP34.5 results in failure to accumulate cytoplasmic and extracellular virions in a celltype-and growth-state-dependent manner (7) . This region of the viral genome is complex, encoding multiple overlapping genes with regulatory functions, so it is not clear that ICP34.5 itself is required for envelopment (1, 8, 34) . Also, the ICP34.5 gene product is required for efficient late protein synthesis in some cells, raising the possibility that the envelopment defect observed may be secondary to a defect in synthesis of other viral late proteins (10, 21) .
Purves et al. (32, 33) have reported that the U L 34 gene product of HSV type 1 (HSV-1) is a membrane-associated phosphoprotein with an M r of Ϸ30,000. Analysis of the predicted sequence of the U L 34 protein suggests that the protein has no cleavable signal sequence but does contain a potential transmembrane domain located near the C terminus. The distribution of charges in the vicinity of the putative transmembrane domain further suggests that U L 34 is likely to be a type II integral membrane protein, with a long, cytoplasmic Nterminal domain and a very short, luminal or extracellular C-terminal domain. These properties suggest that U L 34 may participate in events mediated at the infected cell membranes, such as envelopment of the tegument and nucleocapsid, viral release, expression or activity of the viral envelope glycoproteins, or modification of the activity of cellular membrane proteins. The U L 34 protein coding sequence is well conserved in the alphaherpesviruses for which sequence data are available (15, 16, 43) . Significant sequence similarity is also evident between HSV-1 U L 34 and the human cytomegalovirus (HCMV) U L 50 protein (6) . The HCMV U L 50 gene is also a positional homolog of U L 34; that is, it is found between the U L 49 and U L 51 genes of HCMV, which are homologous to the HSV-1 U L 33 and U L 35 genes, respectively. The U L 50 gene and its relatives in human herpesvirus 6 (HHV-6), HHV- 
MATERIALS AND METHODS

Cells and viruses.
HEp-2, 143B, HEL299, and Vero cells (all from the American Type Culture Collection) were maintained in Dulbecco's modified Eagle's medium (high glucose) supplemented with 5% fetal bovine serum. The properties of HSV-1(F), the thymidine kinase (TK) deletion recombinant ⌬305, and the TK insertion recombinant R7309 (kindly provided by Bernard Roizman) have been previously described (30, 32) .
Plasmid constructions. The structures of the plasmids used for construction of a U L 34-complementing cell line and for construction of a U L 34-null virus are shown in Fig. 1. pRR1060 (Fig. 1B) was constructed by ligating the 17.3-kb BglII-SpeI fragment of the HSV-1(F) genome containing the U L 34 gene into BamHI-and XbaI-digested pGEM-3Z(fϩ). pRR1099 (Fig. 1C) was generated by insertion of a 3.4-kb U L 34 gene-containing fragment of pRR1060 into pcDNA3. The insert fragment was obtained by sequential treatment of pRR1060 with restriction enzyme EcoNI, Klenow enzyme and deoxynucleoside triphosphates to generate blunt ends, and restriction enzyme NheI. This insert was ligated to the large NruI-XbaI restriction fragment of pcDNA3. pRR1072 was generated by replacement of U L 34 sequences in pRB4177 (33) with the coding sequence for a mutant form of green fluorescent protein (GFP). The insert fragment was obtained by sequential treatment of phGFPS65T (Clontech) with restriction enzyme XbaI, Klenow enzyme and deoxynucleoside triphosphates to generate blunt ends, and restriction enzyme NcoI. This insert was ligated to the large NcoI-HpaI restriction fragment of pRB4177. Plasmid pRB166, containing the BamHI Q fragment of HSV-1(F) in pGEM-3Z, used for repairing the TK locus of the virus, was obtained from Bernard Roizman.
Construction of a stably transfected clonal U L 34-complementing cell line. 143/1099 complementing cells were obtained by transfecting 10-cm 2 cultures of 143B cells with 1 g of BglII-linearized pRR1099, using 4 l of LipofectAmine (Gibco/BRL) in Dulbecco's modified Eagle's medium without serum or antibiotics according to the manufacturer's suggested protocol. Two days after transfection, cells were seeded into medium containing 400 g of Geneticin (Gibco/ BRL) per ml. After passage for 2 weeks in selective medium, the cell population was assayed for ability to support plaque formation in the presence of bromodeoxyuridine (BUdR) by a virus stock derived from cotransfection of R7309 viral genomic DNA and pRR1072 plasmid DNA. Ability to complement the U L 34 deletion was indicated by ability to support formation of BUdR-resistant, GFPpositive plaques. Clonal cell lines were derived from the stably transfected population by limiting dilution. Forty-two such lines were assayed for ability to complement U L 34 deletion, and one of these (143/1099E) was chosen, based on number and size of plaques formed, for isolation and growth of U L 34-negative virus.
Recombinant viruses. The genotypes of recombinant viruses used in this study with respect to the TK and U L 34 loci are indicated schematically in Fig. 1D . The U L 34 deletion virus HSV-1(vRR1072) was obtained by cotransfection of 5-cm 2 cultures of Vero cells with 250 ng of HSV-1 R7309 viral genomic DNA and 100 ng of EcoRI-linearized pRR1072 plasmid DNA, using 5 l of LipofectAmine according to the manufacturer's suggested protocol. Viral stock was prepared from the culture after the culture exhibited 100% cytopathic effect. Serial dilutions of this stock were plated on 143/1099E cells in the presence of BUdR to select for TK-negative viruses, and GFP-positive plaques were subjected to three cycles of plaque purification. The homologous U L 34 repair virus vRR1072Rep was obtained by cotransfection of vRR1072 viral genomic DNA and pRR1099 plasmid DNA. GFP-negative plaques were subjected to three cycles of plaque purification. The U L 34-negative TK-positive virus vRR1072(TK ϩ ) for electron microscopic (EM) studies was obtained by cotransfection of vRR1072 viral genomic DNA and pRB166 plasmid DNA. TK-positive viruses were selected in hypoxanthine-aminopterin-thymidine medium as described elsewhere (30) and subjected to three cycles of plaque purification.
Fractionation of nuclear lysates for capsid analysis. Nuclear lysates were prepared and fractionated by a modification of the method described by Lamberti and Weller (26) . Confluent monolayer cultures of Vero cells (25 cm 2 ) that had been infected at a multiplicity of infection of 10 for 20 h were washed twice with phosphate-buffered saline (PBS), scraped into 1 ml of PBS, and pelleted at low speed in a microcentrifuge. The cell pellet was resuspended in 0.4 ml of PBS containing 0.5% NP-40 and incubated on ice for 1 min to lyse the cells. Nuclei were pelleted from the suspension by centrifugation at 2,000 rpm for 5 min. Nuclei were resuspended in 0.25 ml of PBS containing 0.5% NP-40 and then lysed by a single cycle of freezing and thawing followed by sonication three times for 10 s each. Debris was pelleted for 2 min at top speed in the microcentrifuge, and then nonencapsidated DNA was digested by adding MgCl 2 to 2 mM and 5 U of RQ1 DNase (Promega) and allowing the reaction to proceed at 37°C for 30 min. The nuclear extract was fractionated by centrifugation on a 10-ml 15 to 45% sucrose gradient made up in PBS at 35,000 rpm for 30 min. Gradients were separated into 20 0.5-ml fractions taken by dripping from the bottom of the tube. For analysis of DNA, 0.2-ml aliquots of each fraction were mixed with an equal volume of 10 mM EDTA-1% sodium dodecyl sulfate (SDS)-50 g of glycogen per ml and extracted with an equal volume of 1:1 phenol-chloroform. DNA was precipitated from the aqueous phase with ethanol, resuspended in Tris-EDTA, and applied to an agarose gel. For analysis of capsid protein, 0.2-ml aliquots of each fraction were adjusted to 12% trichloroacetic acid (TCA) after addition of 10 g of bovine serum albumin as carrier, allowed to react on ice for 30 min, and then centrifuged in a microcentrifuge for 5 min to pellet precipitated protein.
Pellets were washed once in 12% TCA, three times with cold acetone to remove residual TCA, dried, and then resuspended in SDS-polyacrylamide gel electrophoresis (PAGE) sample buffer.
Isolation and analysis of RNA. Total RNA was isolated and analyzed by Northern blotting as previously described (36) .
SDS-PAGE and immunoblotting. Proteins were separated by SDS-PAGE, electrically transferred to a nitrocellulose sheet, and probed with antibodies as previously described (38) . Anti-U L 34 rabbit antiserum and anti-U S 11 monoclo- nal antibody have been previously described (33, 38) . Anti-gD and anti-gE antibodies were obtained from the Goodwin Institute. Anti-VP5 monoclonal antibody was obtained from Biodesign International. Measurement of virus replication in single-step growth. Cultures of Vero, 143B, 143/1099E, HEL299, and HEp-2 cells were exposed to virus at a multiplicity of infection of 10 for 90 min at 4°C to allow attachment of virus. The inoculum was then aspirated, and cells were washed three times in 37°C PBS and placed at 37°C in growth medium. This was designated time zero of infection. After incubation for 90 min to allow virus entry and initiation of infection, cells were washed once with citrate buffer (50 mM sodium citrate, 4 mM KCl, adjusted to pH 3.0 with HCl) and then incubated in a second wash of citrate buffer for 1 min to inactivate most of the residual virus. Monolayers were then washed twice in PBS and incubated in growth medium for the remainder of the infection. At various times, cultures were frozen at Ϫ80°C and then thawed to lyse the cells, diluted 1:1 with autoclaved skim milk, and sonicated with a Fisher Sonic Dismembrator at power level 0 for 20 s to fully disrupt cells and release virus particles. The virus stocks were then titrated on 143/1099E cell monolayers as described below.
Plaque assays. Cultures of 143/1099E, 143B, Vero, or HEL299 cells that were roughly 70% confluent were exposed to virus at 37°C for 90 min and then incubated in growth medium containing 0.01% pooled human immune globulin (Gammar, Armour Pharmaceutical) for 48 h to permit virus plaque formation. Plaques were visualized either by GFP fluorescence or by immunoassay using a monoclonal antibody directed against HSV-1 gD (Goodwin Cancer Research Laboratories) as previously described (37) .
Transmission EM of infected cells. Confluent Vero cell monolayers were infected at a multiplicity of infection of 10 for 20 h and then fixed by incubation in 2.5% glutaraldehyde in 0.1 M cacodylate buffer (pH 7.4) for 2 h. Cells were postfixed in 1% osmium tetroxide, washed in cacodylate buffer, dehydrated, embedded in Spurr's resin, and cut into 95-nm sections. Sections were mounted on grids, stained with uranyl acetate and lead citrate, and examined with a Hitachi 7000 model transmission electron microscope.
RESULTS
Construction of a recombinant U L 34 deletion virus.
To create a U L 34-null recombinant virus, we created a plasmid (pRR1072) in which U L 34 coding sequences between the NcoI site (which includes the U L 34 initiator methionine) and an HpaI site 682 nucleotides 3Ј to the initiator methionine were replaced with the coding sequence for GFP, including a stop codon (Fig. 2B) . This substitution removes the sequences coding for amino acids 1 to 228 of U L 34 but does not disturb the coding sequence for U L 33 or U L 35. The U L 34 coding sequences remaining have no methionine codons that might support initiation and expression of a fragment of U L 34. HSV-1 R7309 (Fig. 1D) is derived from the TK-negative recombinant ⌬305 by insertion of an ␣27-TK fusion immediately upstream of the U L 34 protein coding sequence (32) . Cotransfection of pRR1072 with HSV-1 R7309 DNA results in production of progeny in which the inserted ␣27-TK fusion and the wild-type U L 34 sequences are replaced by sequences with the GFP substitution. These progeny are then TK negative (and therefore BUdR resistant) and GFP positive. Cotransfection of R7309 and pRR1072 gave rise to no BUdR-resistant, GFP-positive plaques, suggesting that expression of U L 34 is essential for efficient propagation of the virus. A complementing cell line was constructed by stable transfection of 143B cells with pRR1099 and screening of clonal cell lines for the ability to support formation of BUdR-resistant, GFP-positive virus following infection with the R7309-pRR1072 cotransfection stock. Progeny having the desired phenotypes were plaque purified on the complementing cell line, amplified, and characterized with respect to genome structure and U L 34 protein expression. One of these isolates, designated HSV-1 vRR1072, was chosen for further study. A homologous repair virus for vRR1072, designated vRR1072Rep, was constructed by co- transfection of recombinant viral DNA with pRR1099 and purification of GFP-negative plaques. The genome structures of the U L 34 deletion and repair viruses were assessed by Southern blotting. The sequence of the U L 34 gene is contained within a 6.7-kb NotI restriction fragment in wild-type virus. This fragment is subdivided into 4.6-and 2.1-kb fragments in the U L 34 deletion due to the introduction of a NotI site in the GFP sequences. Viral DNA was digested with restriction endonuclease NotI, electrophoretically separated, and probed first with Southern probe I, which detects sequences that are deleted in the U L 34-negative recombinant (Fig. 1C) . As expected, a band of 6.7 kb is detected in ⌬305 and vRR1072Rep, but no signal is observed in DNA from vRR1072, suggesting that the U L 34 coding sequences are missing in the recombinant and that the recombinant is not contaminated by significant amounts of wild-type virus. Southern probe II spans the sequences deleted in vRR1072 and was expected to detect the full-length 6.7-kb NotI fragment in wild-type virus and the two subfragments produced in the U L 34 recombinant. After the blot shown in Fig. 1C was stripped and reprobed with Southern probe II, the 4.6-and 2.1-kb fragments were observed in the U L 34-negative recombinant but not in ⌬305 or vRR1072Rep. The virus genome thus has the expected structure.
To test for U L 34 protein expression from the viral genome, Vero cells were either mock infected or infected for 18 h with ⌬305, vRR1072, and vRR1072Rep, and cellular lysates were prepared, separated on an SDS-polyacrylamide gel, blotted to nitrocellulose, and probed with anti-U L 34 antiserum (Fig. 2E) . Equivalent amounts of total protein were loaded, as shown by equivalent Coomassie blue staining of identical samples run on the same gel (not shown). A strong signal is observed at M r ϳ30,000 in ⌬305 and the repair virus, but no signal is detectable in proteins from cells infected with the U L 34-negative recombinant.
Expression of the U L 33, U L 34, and U L 35 mRNAs was examined in wild-type and deletion viruses by Northern blotting. The normal kinetics of expression for U L 33 and U L 34 were examined in a time course experiment with and without the DNA replication inhibitor phosphonoacetic acid (PAA). Total RNA was harvested from Vero cells infected with 10 PFU of HSV-1(F) per cell and treated or not treated with 300 g of PAA per ml throughout the infection. At various times after infection, total RNA was purified, electrophoretically separated, blotted to a nylon membrane, and probed with a 32 Plabeled RNA antisense to U L 33 and U L 34 (Fig. 3A) . Equal A 260 units of total RNA were loaded into each lane, and equivalence of sample loading was confirmed by examination of rRNA staining intensity in each lane (not shown). In the absence of PAA, U L 33 and U L 34 RNAs are expressed with identical kinetics. Maximal expression of both RNAs is achieved by 8 h after infection and is maintained until late in the infectious cycle. Expression of both RNAs is partially sensitive to PAA. Early expression occurs in the presence of PAA, but late expression is not maintained, suggesting that these RNAs are expressed with leaky-late, or gamma-1, kinetics. To examine RNA expression in the deletion virus, total RNA was harvested from Vero cells infected for various times with ⌬305, vRR1072, or vRR1072Rep, and equal amounts of total RNA were electrophoretically separated, blotted, and probed with the probe used for Fig. 3A (Fig. 3B and C) . RNA samples for detection of U L 33 and U L 34 were separated on 1.3% agarose gels; those for U L 35 detection were separated on 1.8% agarose gels. In the deletion virus, as in ⌬305 and the repair virus, U L 33 and U L 34 mRNAs (Fig. 3B) are expressed in parallel and are first detectable at the same time, but both RNAs accumulate more slowly in the deletion virus-infected cells. Maximal amounts of U L 33 and U L 34 mRNAs are not achieved until 24 h after infection. In contrast, U L 35 mRNA accumulates in deletion virus-infected cells at levels similar to those in cells infected with wild-type and repair viruses at all time points tested, suggesting that the deletion in U L 34 has no significant effect on transcription of U L 35.
U L 34 expression is required for production of normal viral plaques. To determine the importance of U L 34 expression in plaque formation, noncomplementing 143B cells and complementing 143/1099E cells were infected at low multiplicity and plaques were allowed to develop for 48 h. Monolayers were then examined for formation of fluorescent plaques with a fluorescence microscope. On complementing cells, the U L 34 deletion virus made robust plaques containing hundreds of infected cells (Fig. 4A) . These plaques were syncytial, since the recombinant ⌬305, from which vRR1072 is derived, is syncytial due to deletion of a part of the U L 24 gene (23, 30, 40) . On noncomplementing cells, the virus forms only minute plaques, containing two to fewer than ten cells (Fig. 4B) . Plating efficiency of the U L 34 deletion virus on Vero and HEL299 cells was compared to that of ⌬305 and vRR1072Rep viruses ( Table  1 ). The plating efficiency was found to depend on the cell type. On HEL299 cells, the U L 34 deletion virus formed as many plaques as ⌬305 and the repair virus, whereas on Vero cells many fewer plaques formed. On all cell lines tested, the plaques formed by the U L 34 deletion were minute, consisting of only a few infected cells (not shown). On Vero cells, numerous individual infected cells were observed but were not counted as plaques.
U L 34 expression is required for efficient single-step growth of HSV-1. Plaque formation is a complex process whose success is determined by the efficiencies of single-step growth, viral egress, and cell-cell spread. To determine whether the deficiency in plaque formation might reflect a deficiency in infectious virus production, monolayer cultures of noncomplementing 143B and 143/1099E cells were infected with vRR1072 at a multiplicity of infection of 10, washed with PBS and treated with pH 3.0 buffer to remove and inactivate most of the residual virus, and incubated at 37°C to allow virus growth. At various times after infection, virus stocks were prepared from the total infected culture (cells and medium together) or from culture medium alone, and stocks were titered on complementing 143/1099E cells (Fig. 5A) . Replication of vRR1072 on 143/1099E cells showed typical kinetics, with an increase of viral titer in the culture of several log orders of magnitude. The yield of virus on these cells was, however, about a log order of magnitude less than is typical of a wild-type virus on these cells (not shown), suggesting that complementation is incomplete. About 10% of the virus produced in complementing cell culture is released to the extracellular medium. On noncomplementing 143B cells, total viral yield in the culture is reduced more than 2 log orders of magnitude, suggesting that U L 34 expression is necessary for efficient production of infectious virus. A similar fraction of the infectivity produced (about 10%), however, is released to the extracellular medium, suggesting that infectious particles produced can egress from the cell. To assess the cell type dependence of U L 34 function, and to compare wild-type and deletion yields outside of a complementing cell system, single-step growth kinetics of the U L 34-expressing ⌬305 and vRR1072Rep and of the U L 34 deletion virus were measured on HEp-2, Vero, and HEL299 cells (Fig.  5B to D) . In all of these cell types, the deletion virus produced three to more than four log orders of magnitude less virus than ⌬305. Replication of the repair virus was indistinguishable from that of ⌬305, suggesting that the defect in single-step replication was due specifically to the deletion of U L 34 sequences in vRR1072.
The defect in the U L 34-negative virus is not due to a global failure of viral gene expression. The kinetics and membrane association of U L 34 protein suggest a role in virion maturation or egress, but the large defect in U L 34-null virus replication is consistent with a variety of explanations, such as failure of steps prior to virion assembly, including DNA replication and gene expression. To test these possibilities Vero cells infected with ⌬305, vRR1072, and vRR1072Rep were labeled with [ 35 S]methionine for 2 h at various times after infection, and labeled proteins were separated by SDS-PAGE. Separated proteins were stained with Coomassie blue to assess loading (not shown) and visualized by autoradiography (Fig. 6) . The patterns of protein synthesis in wild-type and U L 34-negative viruses are highly similar, with two exceptions: (i) a band of the size expected for the U L 34 protein is present in protein from cells infected with ⌬305 and vRR1072Rep but not vRR1072, and (ii) a band of the size expected for GFP is present in protein from cells infected with vRR1072 but not ⌬305 and vRR1072Rep. Some specific late proteins such as VP5 (at about 150,000) and VP16 (at about 68,000) are distinguishable in the patterns and are synthesized at the same level in cells infected with all viruses, suggesting that DNA replication and the replication-dependent late protein synthesis occur normally in cells infected with the deletion virus. To test specifically for late protein expression, SDS-PAGE-separated proteins from cells infected for 16 h with these same viruses were blotted to nitrocellulose and probed for gD (Fig. 7A), gE (Fig.  7B) , and U S 11 (Fig. 7C ). gD and gE are both gamma-1, or leaky-late, gene products; U S 11 is a gamma-2, or true-late, gene product (25, 41) . Equivalent amounts of each of these proteins were accumulated in cells infected with all three viruses.
U L 34 is not required for generation of DNA-containing capsids. Nuclear lysates were made from cells infected for 16 h with ⌬305 or vRR1072, digested with DNase, and fractionated on 15 to 45% sucrose gradients. To test for viral genomes, DNA was purified from aliquots of gradient fractions and separated on agarose gels (Fig. 8A and C) . The sedimentation position of capsid structures was detected by Western blotting of TCA-precipitated aliquots of gradient fractions and probing with antibody directed against the major capsid protein VP5 (Fig. 8B and D) . The amounts of DNase-resistant, rapidly sedimenting DNA are identical in wild-type and deletion mutant-derived gradients, suggesting that encapsidation of viral genomes occurs in cells infected with both viruses. Similarly, the amounts of rapidly sedimenting capsid protein are similar in nuclei of cells infected with both viruses. The greater amount of protein sedimenting as empty capsids in vRR1072-infected cells in this experiment was not a consistent feature of these experiments. of stages of maturation are evident; these particle include capsids in the process of envelopment at the inner nuclear membrane (Fig. 9A) , enveloped virus particles between the inner and outer nuclear membrane (Fig. 9B) , enveloped virus particles in vesicles in the cytoplasm (Fig. 9A) , and enveloped virus particles studding the surface of the cells and in the spaces between adjacent cells (Fig. 9A) . Representative U L 34 deletion-infected cells are shown in Fig. 9C 9D ). All of these were surrounded, but not completely bounded, by membranes.
DISCUSSION
We have observed that deletion of coding sequences within the U L 34 gene of HSV-1 results in defects in single-step growth and plaque formation in the deletion virus. The defect in plaque formation is likely to be caused by the profound defect in single-step viral replication. These phenotypes are specifically due to deletion of the U L 34 sequences, since (i) Southern and Western blotting experiments show that U L 34 protein coding sequences are missing in the deletion virus and that no detectable U L 34 protein is expressed; (ii) the observed defects in plaque formation and single-step growth can be obviated either by complementation in trans or by homologous repair of the U L 34 locus; and (iii) there is no evidence for a specific or general failure to express other viral proteins (Fig.  6 ). While the deletion virus accumulates U L 33 mRNA somewhat more slowly than the wild-type virus, this is unlikely to be responsible for the phenotypes observed. The U L 33 protein is essential for packaging of viral DNA into capsids in the nucleus (2, 13 (Fig. 9) .
Several considerations suggest that the failure of single-step replication by the U L 34 deletion virus is due to failure to envelop DNA-containing capsids at the inner nuclear envelope. (i) In noncomplementing cells, the virus successfully completes all of the events that precede envelopment during infection. All classes of viral protein are synthesized at normal levels, including late gene products, suggesting that there is no defect in overall gene expression or in replication of the viral DNA. Both EM and gradient fractionation of nuclear lysates provide evidence that the virus produces and packages viral DNA into capsids at normal levels. We cannot yet exclude the possibility that the DNA packaging observed in the absence of U L 34 is not fully completed. Shao et al. observed that a virus unable to express the viral alkaline nuclease was also able to produce normal amounts of B and C capsids in the nucleus but was unable to envelop those capsids (42) . They suggested that this failure might be due to a defect in a very late stage of DNA packaging. Because of the association of U L 34 with cellular membranes, we favor the hypothesis that U L 34 is responsible for recruiting or mediating interactions between some components of the envelopment complex. (ii) EM analysis of cells infected with the U L 34 deletion virus shows no evidence of enveloped virus particles either in the cell cytoplasm or on the surface of the cells. Defects in maturation of the virus particles that occur later than primary envelopment should be evidenced by the presence of enveloped or unenveloped virus particles in the cytoplasm as seen in U L 20 or gK deletion viruses (5, 22, 24) . Though enveloped virus particles were not observed in EM analysis of deletion virus-infected cells, due to their rarity, the results of single-step growth analysis suggest that infectious particles are produced at low levels in all cells tested. At least in 143B cells, a normal fraction of these particles is released to the extracellular medium with kinetics similar to that seen for wild-type virus. It is not clear whether the virus released to the medium in the noncomplementing cells represents the product of normal egress or, possibly, the result of the disruption of infected cells that gives rise to the cellular remnants observed in deletion virus-infected cultures (Fig. 9F) .
A second unusual feature of the deletion virus-infected cells is production of cellular remnants containing highly condensed material, possibly derived from the nucleus, surrounding an accumulation of capsids and surrounded by cellular membranes. These remnants are very similar to so-called apoptotic bodies (reviewed in reference 12), which also have shrunken nuclei containing highly condensed chromatin surrounded by a condensed cytoplasm. The U L 34 protein is a substrate for the U S 3 protein kinase. This kinase has been reported to play a role in protection of infected cells from apoptosis (3, 20, 27) . It is possible that U L 34 protein participates in the antiapoptotic function of U S 3. In HSV-1, deletion of the U S 3 gene does not result in detectable impairment of single-step viral replication (31) , suggesting that phosphorylation of U L 34 by U S 3 is not required for the essential function of U L 34 in viral maturation. However, it has been reported that in pseudorabies virus (PRV), deletion of the U S 3 homolog results in a defect in viral egress (44) . While it is not yet known if a PRV U L 34 homolog exists and is phosphorylated by the PRV U S 3 homolog, it is tempting to speculate that the egress defect observed in U S 3-negative PRV may be due to a failure to phosphorylate U L 34.
The U L 34 gene is conserved in the genomes of all human herpesviruses, suggesting that it may function similarly in these diverse viruses. The function may not, however, be identical in all species. It is clear that there are critical species-dependent differences in the pathways for egress, since the phenotypes of similar mutations are species specific. For example, the U L 20 gene products of HSV and PRV are both required for trafficking of enveloped virus particles to the cell surface. Deletions that remove these genes result in accumulation of enveloped particles within intracellular membranes (5, 18) . The sites of accumulation differ, however, with HSV accumulating in the perinuclear space and PRV accumulating in cytoplasmic vesicles. The U L 3.5 genes of PRV and bovine herpesvirus 1 appear to function in reenvelopment of nucleocapsids in the cytoplasm of infected cells, but no homolog of this gene is found in HSV (17, 19) . Whether the function of the HSV-1 U L 34 gene product is identical to that of the counterpart gene products of other herpesviruses remains to be determined.
